PHERGain Phase 2 Trial: HER2-Positive Breast Cancer De-escalation and ctDNA Analyses
The 5-year results from the randomized phase 2 PHERGain trial demonstrate that tailoring chemotherapy in HER2-positive early breast cancer based on early PET scans maintains high invasive disease-free survival rates ... Read More